Rituximab Benefit in MCL
This ongoing phase II trial examined the efficacy of rituximab when added to ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL). Findings were presented at the 2014 American Society of Hematology annual meeting. Of the 50 patients with MCL, 45 were evaluable. The overall response rate (ORR) was 87% (n = 39) with complete response in 17 patients (38%) and partial response in 22 patients (49%). Among those with Ki-67 <50%, the ORR was 100%; in those with Ki-67 ≥50%, the ORR was 50%.
Read more here.